Lipid Luminations

Host: Matt Birnholz, MD Guest: William Gray, MD When compared to the options available to coronary artery disease patients, advances in treatment for peripheral artery disease have unfortunately been lacking. But now that’s all changing with the introduction of drug-eluting stents as a treatment option, as explained by the President of Lankenau Heart Institute at Main Line Health Dr. William Gray.

Host: Alan S. Brown, MD, FACC, FAHA, FNLA Live from the Clinical Lipid Update of the National Lipid Association in Amelia Island, FL, host Dr. Alan Brown welcomes Dr. Robert Kloner, Vice President of Translation at Huntington Medical Research Institutes and Professor of Medicine in the Cardiovascular Division of Keck School of Medicine at the University of Southern California. Dr. Kloner discusses the cardiovascular risk factors associated with erectile dysfunction, safety and efficacy of erectile disfunction drugs, and benefits vs risks of supplementing with testosterone.

Host: Alan S. Brown, MD, FACC, FAHA, FNLA Live from the Clinical Lipid Update of the National Lipid Association in Amelia Island, FL, host Dr. Alan Brown welcomes Dr. Rhoda Cooper-DeHoff. Dr. Cooper-DeHoff is an Associate Professor in the Department of Pharmacotherapy and Translational Research and Division of Cardiovascular Medicine of the Colleges of Pharmacy and Medicine at the University of Florida. She is also Associate Director of the Center for Pharmacogenomics at this institution. Dr. Cooper-DeHoff discusses the rise of pharmacometabolomics, genomic testing, and pharmacogenetic testing in lipidology, with particular emphasis on predictive mapping for statin responses.

Host: Alan S. Brown, MD, FACC, FAHA, FNLA Live from the Clinical Lipid Update of the National Lipid Association in Amelia Island, FL, host Dr. Alan Brown welcomes Dave Dixon, PharmD, Clinical Pharmacist and Associate Professor of Pharmacology at Virginia Commonwealth University School of Pharmacy. Dr. Dixon is also a Board Certified Pharmacotherapy Specialist, Clinical Lipid Specialist, and Fellow of the National Lipid Association. He serves as a Regional Representative for the Southeast Chapter of NLA and on the Journal of Clinical Lipidology Editorial Board. Dr. Dixon discusses guidelines for treating hypertriglyceridemia, effective therapies for reducing triglyceride levels, and emerging lipid-lowering therapies in development.

Host: Alan S. Brown, MD, FACC, FAHA, FNLA Live from the Clinical Lipid Update of the National Lipid Association in Amelia Island, FL, host Dr. Alan Brown welcomes Dr. Eugenia Gianos. Dr. Gianos is an assistant professor in the Department of Medicine and co-clinical director of the Center for the Prevention of Cardiovascular Disease at the NYU School of Medicine. Dr. Gianos discusses the effectiveness, potential side effects, and patient outcomes with PCSK9 antibodies for management of dyslipidemia.

Host: Alan S. Brown, MD, FACC, FAHA, FNLA Patients in lipidolgy clinics sometimes undergo diagnostic workups for mild liver enzyme elevations, and in select cases a diagnosis of non-alcoholic fatty liver disease will be made. How does this diagnosis compare with the more inflammatory alcoholic fatty liver disease, and what roles should the lipidologist play in response to these findings? Dr. David Cohen, Professor of Medicine at Harvard Medical School and Director of Hepatology at Brigham and Women's Hospital, joins host Dr. Alan Brown to discuss the pathogenesis and management of non-alcoholic fatty liver disease.

Host: Alan S. Brown, MD, FACC, FAHA, FNLA Like in the United States, Canadian citizens contend with a high pediatric prevelance of lipid disorders, particularly familial hypercholesterolemia. However, perspectives on clinical care and standards public health priorities to address dyslipidemia differ markedly between these two countries. Can American practitioners and health policy experts alike benefit from Canadian approaches to lipidology? Dr. Alan Brown welcomes Dr. Julie St. Pierre, Professor of Pediatrics at Sherbrooke University in Canada, to discuss pediatric lipid disorder management across North American borders.

Host: Alan S. Brown, MD, FACC, FAHA, FNLA Joining Dr. Alan Brown to discuss the pharmacokinetic data behind drug interactions between treatments for complex lipid abnormalities is Dr. Barbara Wiggins, Pharm.D, clinical pharmacy specialist in cardiology at the Medical University of South Carolina and adjunct professor at the South Carolina School of Pharmacy. Dr. Wiggens has served as a member of the cardiovascular expert panel for the United States Pharmacopoeia.

Host: Alan S. Brown, MD, FACC, FAHA, FNLA Guest: Robert Wild, MD, MPH, D.Phil. Recorded live at the recent Annual National Lipid Association meeting, Dr. Alan Brown welcomes Dr. Robert Wild to discuss types of dyslipidemia that clinicans may see in women of child bearing age, particularly those using hormonal contraception. The two discuss ways for clinicians to trace the source of dyslipidemia in these women, from primary to secondary causes, and how this knowledge can guide future contraception choices. Dr. Robert Wild is Professor of OB/GYN and Adjunct Professor in Biostatistics and Epidemiology at the University of Oklahoma. He is also Adjunct Professor in Epidemiology at the University of Pittsburgh, and Adjunct Professor of Nutrition at Oklahoma State University.

Host: Alan S. Brown, MD, FACC, FAHA, FNLA Guest: Joyce Ross Host Dr. Alan Brown welcomes Joyce Ross, nurse practitioner and President of the National Lipid Association. Joyce is a consultative education specialist in Cardiovascular Risk Intervention with the University of Pennsylvania Health System. She is the first Nurse Practitioner elected as President of the NLA. Ms. Ross introduces her goals for the upcoming year, including novel efforts on behalf of the NLA to help combat America's obesity epidemic.

Host: Alan S. Brown, MD, FACC, FAHA, FNLA Host Dr. Alan Brown welcomes Dr. Seth Martin, cardiologist and assistant professor of medicine at the Johns Hopkins University School of Medicine with a joint appointment in epidemiology at the Johns Hopkins Bloomberg School of Public Health. Dr. Martin is a faculty member in the Johns Hopkins Ciccarone Center for the Prevention of Heart Disease. Dr. Martin discusses the pursuit of lipid profiles on a national level, utilizing Big Data from health records and clinical trials to develop better understandings of cardiovascular risk and theraputic efficacies.

Host: Alan S. Brown, MD, FACC, FAHA, FNLA Guest: Joyce Ross, MSN, CRNP, CS, CLS, FNLA, FPCNA Host Dr. Alan Brown welcomes Joyce Ross, MSN, CRNP, FNLA, President-Elect of the National Lipid Association. Joyce serves as a consultative education specialist in cardiovascular risk intervention with the University of Pennsylvania Health System. Their discussion focuses on lipid management to reduce atherosclerotic cardiovascular disease (ASCVD) risk in elderly patient populations. Thhis interview was recorded live at the National Lipid Association in San Diego, California for the 2016 Spring Clinical Lipid Update.

Host: Alan S. Brown, MD, FACC, FAHA, FNLA Dr. Alan Brown welcomes Dr. Penny Kris-Etherton, Distinguished Professor of Nutrition at Penn State and Past President of NLA. Dr. Kris-Etherton reviews the current dietary recommendations for saturated fat for the population at large and for reducing LDL-C levels. The two discuss the evidence to support these dietary recommendations and optimal replacement nutrients for dietary saturated fatty acids (SFAs).

Host: Alan S. Brown, MD, FACC, FAHA, FNLA Host Dr. Alan Brown welcomes Dr. Steven Nissen, Chairman of the Department of Cardiovascular Medicine and Professor of Medicine at the Lerner School of Medicine of the Cleveland Clinic. The two focus on some of the major developments in lipidology today, from roles of intravascular ultrasound to updates in clinical drug trials to perspectives on past and present guideline recommendations.

Host: Alan S. Brown, MD, FACC, FAHA, FNLA Guest: Harold Bays, MD, FNLA Dr. Alan Brown welcomes Dr. Harold Bays, President of the Southeast Lipid Association and President of the Louisville Metabolic and Atherosclerotic Research Center in Louisville, KY. Dr. Bays led a novel educational effort to provide an annual summary of clinical lipidology to readers of the Journal of Clinical Lipidology. With insightful commentaries of value to lipidologists and generalists alike, the annual summary is expected to pave new ground in the ongoing effort to keep clinicians up to date with the field.

Host: Patrice L Basanta-Henry, MD, MHSc, FACOG Host Dr. Patrice Basanta Henry welcomes Dr Nzinga Harrison, Addiction Medicine & Psychiatrist, Campaign Psychiatrist for Let's Get Mentally Fit!, and, the CMO of ANKA Behavioral Health Incorporated. Dr. Harrison will discuss the importance of non-pyschiatric clinicians in recoginizing mentail illness, those specific illnesses where there is a higher chance of comorbidity of psychiatric illness, and best practices & tools avaialble for health care providers.

Host: Harold Bays, MD, FNLA Dr. Harold Bays welcomes Dr, Alan Remaley, clinical pathologist and Section Chief of the Lipoprotein Metabolism Section in the Cardiopulmonary Branch of the National Heart Lung, and Blood Institute in Bethesda, MD. Their discussion centers on LDL cholesterol from a variety of little-known aspects: its history as a biomarker for disease status, the ways in which it gets specifically measured, and the rise of lipid-altering pharmacotherapies to combat excessive LDL levels.

Host: Alan S. Brown, MD, FACC, FAHA, FNLA Guest: Allan Sniderman, MD Risk is calculated by a variety of algorithms, all of which produce an estimate for that individual based on age, gender, cholesterol, blood pressure, and smoking history. The estimate is critical to clinical decision-making, but how accurate is it? Host Dr. Alan Brown welcomes Dr. Allan Sniderman, Edwards Professor of Cardiology at McGill University, to discuss why we should pay more attention to the causes, and less to the risks, of cardiovascular disease. Supported by an Educational Grant from AstraZeneca.

Host: Alan S. Brown, MD, FACC, FAHA, FNLA Medication Adherence: is it the Achilles Heel in your therapies for patients with dyslipidemia? Dr. Lynne Braun, nurse practitioner in the Preventive Cardiology Center and the Heart Center for Women, and Professor in the Department of Adult Health Nursing at the Rush College of Nursing in Chicago, targets three critical barriers to lipid medication adherance: weak patient-provider relationships, health illiteracy, and poor health care transitions after hospital discharge. Supported by an Educational Grant from AstraZeneca.

Host: Alan S. Brown, MD, FACC, FAHA, FNLA Dr. Alan Brown welcomes Dr. Peter Jones, Associate Professor of Medicine and Atherosclorosis/Lipidology at Baylor College of Medicine in Houston, TX. They review special populations in the treatment of dyslipidemia, including Asians, women, elderly patients, and the immune-compromised. Supported by an Educational Grant from AstraZeneca.